Columbus Circle Investors raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,532,911 shares of the biopharmaceutical company’s stock after buying an additional 136,515 shares during the quarter. Columbus Circle Investors owned about 2.23% of TG Therapeutics worth $18,165,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TGTX. Legal & General Group Plc boosted its holdings in shares of TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 384 shares during the period. Bank of America Corp DE boosted its holdings in shares of TG Therapeutics by 11.0% in the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,395 shares during the period. UBS Group AG lifted its stake in shares of TG Therapeutics by 34.4% during the 1st quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 3,736 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of TG Therapeutics during the 1st quarter worth approximately $170,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of TG Therapeutics during the 2nd quarter worth approximately $156,000. Institutional investors and hedge funds own 50.45% of the company’s stock.
Shares of TG Therapeutics, Inc. (NASDAQ TGTX) traded down $0.17 during trading hours on Monday, hitting $8.15. The stock had a trading volume of 884,622 shares, compared to its average volume of 1,551,969. TG Therapeutics, Inc. has a twelve month low of $4.10 and a twelve month high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. sell-side analysts anticipate that TG Therapeutics, Inc. will post -1.86 earnings per share for the current fiscal year.
TGTX has been the subject of a number of research analyst reports. B. Riley initiated coverage on TG Therapeutics in a research note on Friday. They set a “buy” rating and a $21.50 price target for the company. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. HC Wainwright reissued a “buy” rating and set a $33.00 price target (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. Finally, ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $26.25.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/04/columbus-circle-investors-has-18-17-million-position-in-tg-therapeutics-inc-tgtx.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.